Bank of New York Mellon’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-277,851
| Closed | -$9.3M | – | 4420 |
|
|
2026
Q1 | $9.3M | Sell |
277,851
-343,960
| -55% | -$13.5M | ﹤0.01% | 1973 |
|
|
2025
Q4 | $28.8M | Sell |
621,811
-5,416
| -0.9% | -$297K | 0.01% | 1332 |
|
|
2025
Q3 | $42.4M | Buy |
627,227
+141,362
| +29% | +$10.5M | 0.01% | 1128 |
|
|
2025
Q2 | $40.7M | Buy |
485,865
+183,201
| +61% | +$13.7M | 0.01% | 1122 |
|
|
2025
Q1 | $21.6M | Buy |
302,664
+234,649
| +345% | +$11.4M | ﹤0.01% | 1465 |
|
|
2024
Q4 | $3.06M | Buy |
68,015
+4,260
| +7% | +$221K | ﹤0.01% | 2552 |
|
|
2024
Q3 | $3.22M | Sell |
63,755
-25,044
| -28% | -$1.2M | ﹤0.01% | 2530 |
|
|
2024
Q2 | $3.62M | Buy |
+88,799
| New | +$3.76M | ﹤0.01% | 2489 |
|
|
2024
Q1 | – | Sell |
-9,936
| Closed | -$400K | – | 4299 |
|
|
2023
Q4 | $400K | Buy |
9,936
+449
| +5% | +$12.8K | ﹤0.01% | 3675 |
|
|
2023
Q3 | $280K | Buy |
+9,487
| New | +$57.4K | ﹤0.01% | 3827 |
|
|
2022
Q3 | – | Sell |
-2,818
| Closed | -$8K | – | 4597 |
|
|
2022
Q2 | $8K | Hold |
2,818
| – | – | ﹤0.01% | 4561 |
|
|
2022
Q1 | $9K | Hold |
2,818
| – | – | ﹤0.01% | 4643 |
|
|
2021
Q4 | $17K | Hold |
2,818
| – | – | ﹤0.01% | 4595 |
|
|
2021
Q3 | $39K | Hold |
2,818
| – | – | ﹤0.01% | 4468 |
|
|
2021
Q2 | $48K | Sell |
2,818
-7,984
| -74% | -$135K | ﹤0.01% | 4331 |
|
|
2021
Q1 | $205K | Sell |
10,802
-529
| -5% | -$17.1K | ﹤0.01% | 4050 |
|
|
2020
Q4 | $328K | Buy |
11,331
+3,231
| +40% | +$93.3K | ﹤0.01% | 3791 |
|
|
2020
Q3 | $305K | Buy |
8,100
+2,921
| +56% | +$85.4K | ﹤0.01% | 3714 |
|
|
2020
Q2 | $173K | Buy |
+5,179
| New | +$224K | ﹤0.01% | 3830 |
|
|
2019
Q4 | – | Sell |
-1,069
| Closed | -$24K | – | 4229 |
|
|
2019
Q3 | $24K | Sell |
1,069
-107
| -9% | -$3.41K | ﹤0.01% | 4173 |
|
|
2019
Q2 | $49K | Buy |
+1,176
| New | +$40.6K | ﹤0.01% | 4123 |
|
Bank of New York Mellon's SLNO Position: Q2 2026 in Review
Bank of New York Mellon sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 277,851 shares — an estimated $9.3M sold.
Bank of New York Mellon first reported a position in SLNO in Q2 2019 and held it in 21 quarters. The position peaked at $42.4M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- Bank of New York Mellon reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- Bank of New York Mellon sold 277,851 Soleno Therapeutics shares in Q2 2026, an estimated $9.3M.
- Bank of New York Mellon first reported a position in Soleno Therapeutics in Q2 2019 and held it in 21 quarters.
- Bank of New York Mellon's Soleno Therapeutics position peaked at $42.4M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.